LEK-8827

LEK-8827
Clinical data
Other names6-Methyl-LEK-8842; 6-Methyl-N-methyl-N-(2-propynyl)lysergamide
ATC code
  • None
Identifiers
  • (6aR,9R)-N,7,7-trimethyl-N-prop-2-ynyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-7-ium-9-carboxamide
PubChem CID
PubChem SID
Chemical and physical data
FormulaC21H24N3O+
Molar mass334.443 g·mol−1
3D model (JSmol)
  • CN(CC#C)C(=O)[C@H]1C[N+]([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)(C)C
  • InChI=1S/C21H24N3O/c1-5-9-23(2)21(25)15-10-17-16-7-6-8-18-20(16)14(12-22-18)11-19(17)24(3,4)13-15/h1,6-8,10,12,15,19,22H,9,11,13H2,2-4H3/q+1/t15-,19-/m1/s1
  • Key:FBJAIHMTLDVIBD-DNVCBOLYSA-N

LEK-8827, also known as 6-methyl-LEK-8842 or as 6-methyl-N-methyl-N-(2-propynyl)lysergamide, is a chemical compound of the lysergamide family.[1] It is the 6-methyl derivative of LEK-8842 and is a quaternary ammonium compound.[1] The drug shows almost complete elimination of affinity for serotonin 5-HT2 and α-adrenergic receptors compared to LEK-8842, with no affinity for serotonin 5-HT2 receptors and slight but negligible affinity for α-adrenergic receptors.[1] Its loss of activity was said to probably be due to the increased polarity of the molecule.[1] LEK-8827 was first described in the scientific literature by 1992.[1] It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.[1]

See also

References

  1. ^ a b c d e f Krisch I, Budihna MV, Rucman R (1992). "Structure-activity study of some newly synthesized ergoline derivatives on 5-HT2 receptors and alpha-adrenoceptors in rabbit isolated aorta". Pharmacology. 45 (4): 195–208. doi:10.1159/000138998. PMID 1332086.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.